Tuberculosis 2012: Biology, pathogenesis and intervention strategies; an update from the city of light

Research in Microbiology

Volumn 164, Issue 3, 2013, Pages 270-280

  Gouzy, Alexandre ^a,b   Nigou, Jérôme ^a,b   Gilleron, Martine ^a,b   Neyrolles, Olivier ^a,b   Tailleux, Ludovic ^c   Gordon, Stephen V ^d  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSTITUT PASTEUR   (France)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Infectious diseases; Mycobacteria; Tuberculosis; Virulence

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; ETHIONAMIDE; GAMMA INTERFERON; H56 ANTIGEN; ISONIAZID; PROTEOME; PYRAZINAMIDE; THIOACETAZONE; THIOLACTOMYCIN; TIOCARLIDE; UNCLASSIFIED DRUG; VPM 1002;

ACETYLATION; BACTERIAL CELL; BACTERIUM MUTANT; CELL TRANSPORT; COMPUTER MODEL; DEACETYLATION; EDITORIAL; EVOLUTIONARY ADAPTATION; FRANCE; GENE CONTROL; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE DEFICIENCY; MESENCHYMAL STEM CELL; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RNA SEQUENCE; TH1 CELL; TUBERCULOSIS;

DRUG RESISTANCE, BACTERIAL; GENETIC VARIATION; HOST-PATHOGEN INTERACTIONS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 84875379117     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2012.12.006     Document Type: Editorial

References (72)

1. Aagaard C., Hoang T., Dietrich J., Cardona P.J., Izzo A., Dolganov G., Schoolnik G.K., Cassidy J.P., et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 2011, 17:189-194.
2. Abramovitch R.B., Rohde K.H., Hsu F.F., Russell D.G. aprABC: a Mycobacterium tuberculosis complex-specific locus that modulates pH-driven adaptation to the macrophage phagosome. Mol. Microbiol. 2011, 80:678-694.
3. Arabolaza A., D'Angelo M., Comba S., Gramajo H. FasR, a novel class of transcriptional regulator, governs the activation of fatty acid biosynthesis genes in Streptomyces coelicolor. Mol. Microbiol. 2010, 78:47-63.
4. Arnvig K., Young D. Non-coding RNA and its potential role in Mycobacterium tuberculosis pathogenesis. RNA Biol. 2012, 9:427-436.
5. Arnvig K.B., Comas I., Thomson N.R., Houghton J., Boshoff H.I., Croucher N.J., Rose G., Perkins T.T., et al. Sequence-based analysis uncovers an abundance of non-coding RNA in the total transcriptome of Mycobacterium tuberculosis. PLoS Pathog. 2011, 7:e1002342.
6. Arnvig K.B., Young D.B. Identification of small RNAs in Mycobacterium tuberculosis. Mol. Microbiol. 2009, 73:397-408.
7. Beresford N.J., Mulhearn D., Szczepankiewicz B., Liu G., Johnson M.E., Fordham-Skelton A., Abad-Zapatero C., Cavet J.S., et al. Inhibition of MptpB phosphatase from Mycobacterium tuberculosis impairs mycobacterial survival in macrophages. J. Antimicrob. Chemother. 2009, 63:928-936.
8. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., Wilkinson K.A., Banchereau R., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
9. Bigger J.W. Treatment of staphylococcal infections with penicillin. Lancet 1944, 244:497-500.
10. Bitter W., Houben E.N., Bottai D., Brodin P., Brown E.J., Cox J.S., Derbyshire K., Fortune S.M., et al. Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog. 2009, 5:e1000507.
11. Blasco B., Chen J.M., Hartkoorn R., Sala C., Uplekar S., Rougemont J., Pojer F., Cole S.T. Virulence regulator EspR of Mycobacterium tuberculosis is a nucleoid-associated protein. PLoS Pathog. 2012, 8:e1002621.
12. Boisson-Dupuis S., El Baghdadi J., Parvaneh N., Bousfiha A., Bustamante J., Feinberg J., Samarina A., Grant A.V., et al. IL-12Rbeta1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS One 2011, 6:e18524.
13. Botella H., Peyron P., Levillain F., Poincloux R., Poquet Y., Brandli I., Wang C., Tailleux L., et al. Mycobacterial p(1)-type ATPases mediate resistance to zinc poisoning in human macrophages. Cell Host Microbe 2011, 10:248-259.
14. Botella H., Stadthagen G., Lugo-Villarino G., de Chastellier C., Neyrolles O. Metallobiology of host-pathogen interactions: an intoxicating new insight. Trends Microbiol. 2012, 20:106-112.
15. Bottai D., Di Luca M., Majlessi L., Frigui W., Simeone R., Sayes F., Bitter W., Brennan M.J., et al. Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. Mol. Microbiol. 2012, 83:1195-1209.
16. Bottger E.C. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin. Microbiol. Infect. 2011, 17:1128-1134.
17. Brisse S., Supply P., Brosch R., Vincent V., Gutierrez M.C. "A re-evaluation of M. prototuberculosis": continuing the debate. PLoS Pathog. 2006, 2:e95.
18. Christophe T., Ewann F., Jeon H.K., Cechetto J., Brodin P. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. Future Med. Chem. 2010, 2:1283-1293.
19. Corbiere V., Pottier G., Bonkain F., Schepers K., Verscheure V., Lecher S., Doherty T.M., Locht C., et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS One 2012, 7:e43285.
20. Coussens A.K., Wilkinson R.J., Hanifa Y., Nikolayevskyy V., Elkington P.T., Islam K., Timms P.M., Venton T.R., et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:15449-15454.
21. de Carvalho L.P., Zhao H., Dickinson C.E., Arango N.M., Lima C.D., Fischer S.M., Ouerfelli O., Nathan C., et al. Activity-based metabolomic profiling of enzymatic function: identification of Rv1248c as a mycobacterial 2-hydroxy-3-oxoadipate synthase. Chem. Biol. 2010, 17:323-332.
22. Desvignes L., Wolf A.J., Ernst J.D. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J. Immunol. 2012, 188:6205-6215.
23. Enarson D. TB and IUATLD. Pediatr. Pulmonol. Suppl. 2004, 26:55-56.
24. Festa R.A., Jones M.B., Butler-Wu S., Sinsimer D., Gerads R., Bishai W.R., Peterson S.N., Darwin K.H. A novel copper-responsive regulon in Mycobacterium tuberculosis. Mol. Microbiol. 2011, 79:133-148.
25. Gold B., Pingle M., Brickner S.J., Shah N., Roberts J., Rundell M., Bracken W.C., Warrier T., et al. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:16004-16011.
26. Grode L., Seiler P., Baumann S., Hess J., Brinkmann V., Nasser Eddine A., Mann P., Goosmann C., et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 2005, 115:2472-2479.
27. Grzegorzewicz A.E., Kordulakova J., Jones V., Born S.E., Belardinelli J.M., Vaquie A., Gundi V.A., Madacki J., et al. A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J. Biol. Chem. 2012, 287:38434-38441.
28. Grzegorzewicz A.E., Pham H., Gundi V.A., Scherman M.S., North E.J., Hess T., Jones V., Gruppo V., et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 2012, 8:334-341.
29. Gutierrez M.C., Brisse S., Brosch R., Fabre M., Omais B., Marmiesse M., Supply P., Vincent V. Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis. PLoS Pathog. 2005, 1:e5.
30. Guyer D.M., Henderson I.R., Nataro J.P., Mobley H.L. Identification of sat, an autotransporter toxin produced by uropathogenic Escherichia coli. Mol. Microbiol. 2000, 38:53-66.
31. Hagedorn M., Rohde K.H., Russell D.G., Soldati T. Infection by tubercular mycobacteria is spread by nonlytic ejection from their amoeba hosts. Science 2009, 323:1729-1733.
32. Hoffmann C., Leis A., Niederweis M., Plitzko J.M., Engelhardt H. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3963-3967.
33. Homolka S., Niemann S., Russell D.G., Rohde K.H. Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog. 2010, 6:e1000988.
34. Houben D., Demangel C., van Ingen J., Perez J., Baldeon L., Abdallah A.M., Caleechurn L., Bottai D., et al. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cell. Microbiol. 2012, 14:1287-1298.
35. Houben E.N., Bestebroer J., Ummels R., Wilson L., Piersma S.R., Jimenez C.R., Ottenhoff T.H., Luirink J., et al. Composition of the type VII secretion system membrane complex. Mol. Microbiol. 2012, 86:472-484.
36. Hougardy J.M., Schepers K., Place S., Drowart A., Lechevin V., Verscheure V., Debrie A.S., Doherty T.M., et al. Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS One 2007, 2:e926.
37. Kumar A., Zhang M., Zhu L., Liao R.P., Mutai C., Hafsat S., Sherman D.R., Wang M.W. High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity. PLoS One 2012, 7:e39961.
38. La Rosa V., Poce G., Canseco J.O., Buroni S., Pasca M.R., Biava M., Raju R.M., Porretta G.C., et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 2012, 56:324-331.
39. Layre E., Sweet L., Hong S., Madigan C.A., Desjardins D., Young D.C., Cheng T.Y., Annand J.W., et al. A comparative lipidomics platform for chemotaxonomic analysis of Mycobacterium tuberculosis. Chem. Biol. 2011, 18:1537-1549.
40. Lee M., Lee J., Carroll M.W., Choi H., Min S., Song T., Via L.E., Goldfeder L.C., et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 2012, 367:1508-1518.
41. Lin P.L., Dartois V., Johnston P.J., Janssen C., Via L., Goodwin M.B., Klein E., Barry C.E., et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:14188-14193.
42. Lin P.L., Dietrich J., Tan E., Abalos R.M., Burgos J., Bigbee C., Bigbee M., Milk L., et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J. Clin. Invest. 2012, 122:303-314.
43. Maertzdorf J., Weiner J., Mollenkopf H.J., Bauer T., Prasse A., Muller-Quernheim J., Kaufmann S.H. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7853-7858.
44. Makarov V., Manina G., Mikusova K., Mollmann U., Ryabova O., Saint-Joanis B., Dhar N., Pasca M.R., et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009, 324:801-804.
45. Mendez S., Traslavina R., Hinchman M., Huang L., Green P., Cynamon M.H., Welch J.T. The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob. Agents Chemother. 2009, 53:5114-5121.
46. Mishra B.B., Rathinam V.A., Martens G.W., Martinot A.J., Kornfeld H., Fitzgerald K.A., Sassetti C.M. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat. Immunol. 2013, 14:52-60.
47. Molle V., Kremer L. Division and cell envelope regulation by Ser/Thr phosphorylation: Mycobacterium shows the way. Mol. Microbiol. 2010, 75:1064-1077.
48. Nambiar J.K., Pinto R., Aguilo J.I., Takatsu K., Martin C., Britton W.J., Triccas J.A. Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. Eur. J. Immunol. 2012, 42:385-392.
49. Niederweis M., Danilchanka O., Huff J., Hoffmann C., Engelhardt H. Mycobacterial outer membranes: in search of proteins. Trends Microbiol. 2010, 18:109-116.
50. O'Hare H.M., Duran R., Cervenansky C., Bellinzoni M., Wehenkel A.M., Pritsch O., Obal G., Baumgartner J., et al. Regulation of glutamate metabolism by protein kinases in mycobacteria. Mol. Microbiol. 2008, 70:1408-1423.
51. Pathan A.A., Minassian A.M., Sander C.R., Rowland R., Porter D.W., Poulton I.D., Hill A.V., Fletcher H.A., et al. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine 2012, 30:5616-5624.
52. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., Menozzi F.D. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001, 412:190-194.
53. Picotti P., Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 2012, 9:555-566.
54. Salzman V., Mondino S., Sala C., Cole S.T., Gago G., Gramajo H. Transcriptional regulation of lipid homeostasis in mycobacteria. Mol. Microbiol. 2010, 78:64-77.
55. Sayes F., Sun L., Di Luca M., Simeone R., Degaiffier N., Fiette L., Esin S., Brosch R., et al. Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion: encoded PE-PPE proteins predicts vaccine potential. Cell Host Microbe 2012, 11:352-363.
56. Schnappinger D., Ehrt S., Voskuil M.I., Liu Y., Mangan J.A., Monahan I.M., Dolganov G., Efron B., et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med. 2003, 198:693-704.
57. Scriba T.J., Tameris M., Smit E., van der Merwe L., Hughes E.J., Kadira B., Mauff K., Moyo S., et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am. J. Respir. Crit. Care Med. 2012, 185:769-778.
58. Shi W., Zhang X., Jiang X., Yuan H., Lee J.S., Barry C.E., Wang H., Zhang W., et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011, 333:1630-1632.
59. Simeone R., Bobard A., Lippmann J., Bitter W., Majlessi L., Brosch R., Enninga J. Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death. PLoS Pathog. 2012, 8:e1002507.
60. Stanley S.A., Grant S.S., Kawate T., Iwase N., Shimizu M., Wivagg C., Silvis M., Kazyanskaya E., et al. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 2012, 7:1377-1384.
61. Subbian S., Tsenova L., O'Brien P., Yang G., Kushner N.L., Parsons S., Peixoto B., Fallows D., et al. Spontaneous latency in a rabbit model of pulmonary tuberculosis. Am. J. Pathol. 2012, 181:1711-1724.
62. Tahlan K., Wilson R., Kastrinsky D.B., Arora K., Nair V., Fischer E., Barnes S.W., Walker J.R., et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012, 56:1797-1809.
63. Tobin D.M., Vary J.C., Ray J.P., Walsh G.S., Dunstan S.J., Bang N.D., Hagge D.A., Khadge S., et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010, 140:717-730.
64. Toledo-Arana A., Repoila F., Cossart P. Small noncoding RNAs controlling pathogenesis. Curr. Opin. Microbiol. 2007, 10:182-188.
65. van der Wel N., Hava D., Houben D., Fluitsma D., van Zon M., Pierson J., Brenner M., Peters P.J. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007, 129:1287-1298.
66. van Soolingen D., Hoogenboezem T., de Haas P.E., Hermans P.W., Koedam M.A., Teppema K.S., Brennan P.J., Besra G.S., et al. A novel pathogenic taxon of the Mycobacterium tuberculosis complex, Canetti: characterization of an exceptional isolate from Africa. Int. J. Syst. Bacteriol. 1997, 47:1236-1245.
67. Volkman H.E., Pozos T.C., Zheng J., Davis J.M., Rawls J.F., Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010, 327:466-469.
68. Wagner T., Bellinzoni M., Wehenkel A., O'Hare H.M., Alzari P.M. Functional plasticity and allosteric regulation of alpha-ketoglutarate decarboxylase in central mycobacterial metabolism. Chem. Biol. 2011, 18:1011-1020.
69. Ward S.K., Abomoelak B., Hoye E.A., Steinberg H., Talaat A.M. CtpV: a putative copper exporter required for full virulence of Mycobacterium tuberculosis. Mol. Microbiol. 2010, 77:1096-1110.
70. Watanabe S., Zimmermann M., Goodwin M.B., Sauer U., Barry C.E., Boshoff H.I. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog. 2011, 7:e1002287.
71. Wolschendorf F., Ackart D., Shrestha T.B., Hascall-Dove L., Nolan S., Lamichhane G., Wang Y., Bossmann S.H., et al. Copper resistance is essential for virulence of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:1621-1626.
72. Xu H., Hegde S.S., Blanchard J.S. Reversible acetylation and inactivation of Mycobacterium tuberculosis acetyl-CoA synthetase is dependent on cAMP. Biochemistry 2011, 50:5883-5892.